Industry
US Pharma Resume Guide 2026: FDA cGMP Standards, ATS Formats & Free Builder
Master the US pharmaceutical resume format in 2026. Covers FDA 21 CFR compliance terms, 1-2 page US resume rules, major US biopharma hubs (Boston, SF Bay, NJ, NC Triangle), and free ATS resume tools.

Industry
Global Pharma Talent Corridor: Writing a Cross-Border CV for India, Ireland, UK & US Roles
The ultimate 2026 guide for international life science professionals moving between India, Ireland, the UK, and the US. Learn how to format GxP experience, CDMO backgrounds, and visa-ready ATS CVs.

Industry
ABPI Impact Map Highlights ยฃ20.4B Pharma Footprint as UK-Ireland Supply Chain Synergies Deepen
The ABPI launches its updated 2026 Pharmaceutical Impact Map, revealing a ยฃ20.4bn economic contribution, 125,702 skilled jobs, and 3,658 NHS collaborations across the UK, while underscoring vital cross-border manufacturing and trade synergies with Ireland.

Industry
GEODIS Expands European Logistics Network with 2,000-Pallet Temperature-Controlled Manchester Pharma Hub
GEODIS opens a state-of-the-art GDP-compliant pharmaceutical hub in Sharston Green, South Manchester, offering 2,000 pallet positions, 15-25ยฐC and 2-8ยฐC climate-controlled storage, and direct air/sea connectivity to Ireland and global markets.

Industry
Registrations Open for TechIreland National AI Challenge 2026: Agentic Workflows, Regional Hubs, and Ecosystem Collaboration
Registrations are now open for the 2026 TechIreland National AI Challenge, delivered in partnership with CeADAR, Enterprise Ireland, and the European Digital Innovation Hubs Network. Learn about the 2026 theme "AI & Agents", key deadlines, regional hubs, and how to register.

Biotechnology
Ireland's Biopharma Manufacturing Hub: A Master Guide to Tax, Talent, CDMO Sourcing, and Regulatory Excellence
An in-depth analysis of Ireland's evolution into Europe's second-largest exporter of medicinal products. Discover how a 12.5% tax structure, NIBRT bioprocessing excellence, HPRA regulatory trust, and a thriving CDMO ecosystem make Ireland the premier location for global drug production.

Industry
Master the Ireland & EU Pharma CV in 2026: HPRA Standards, ATS Templates & Industry Examples
The definitive 2026 guide to writing an ATS-compliant biopharmaceutical CV in Ireland and the EU. Features HPRA & EU Annex 1 standards, GxP bullet point formulas, Irish regional hub insights, and free ATS CV Studio tools.

Industry
Enterprise Ireland Funding Programmes 2026: The Complete Founderโs Guide to Grants, Pre-Seed (PSSF), iHPSU & Founder Visas
Master Enterprise Ireland's funding ecosystem: from Pre-Seed Start Fund (โฌ50k-โฌ100k) and Innovative HPSU Fund (โฌ1.2M) to R&D, Green, and Digitalisation vouchers. Includes step-by-step application advice, readiness timelines, and non-EU founder visa rules.

Industry
The โฌ8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies
The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s โฌ8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.

Regulatory Affairs
After the Mother of All Deals: A Blueprint for the Ireland-India Pharmaceutical Corridor Under the EU-India FTA
A commercial-grade blueprint for the Ireland-India pharma corridor under the EU-India FTA: tariffs, HPRA-CDSCO bridges, 2030 projections, policy asks.

Regulatory Affairs
The UK-India CETA: A Deep Dive into Bilateral Pharmaceutical Value Chains, API Trade, and Medicine Price Trajectories
An in-depth commercial analysis of the UK-India Comprehensive Economic and Trade Agreement (CETA), exploring its transformative impact on bilateral pharmaceutical manufacturing, active pharmaceutical ingredient (API) supply chains, and consumer medicine pricing.

Biotechnology
Bilateral Breakthrough: How the Historic UK-India Free Trade Agreement Transforms Life Sciences and Key Trade Sectors
The historic UK-India Comprehensive Economic and Trade Agreement (CETA) and Double Contributions Convention have officially entered into force, opening duty-free access for pharmaceuticals, dismantling high tariffs on manufacturing inputs, and eliminating dual social security taxes for mobile professionals.
